🔴 Outlook Therapeutics is trading 9.4% down today after its discounted $55 million public offering

Outlook Therapeutics is trading 9.4% down now at $0.81 after continued selling following its discounted $55 million public offering.

• Financing: 55.6 million shares and an equal number of immediately exercisable warrants at $0.99 per share-and-warrant unit, creating substantial dilution and warrant overhang.
• The August 14 third-quarter report and corporate update added uncertainty; management previously indicated limited cash runway while reaffirming a late-2026 LYTENAVA launch.
• The broader market is essentially flat, making company-specific financing and earnings concerns the clearest drivers.